KHPG announced that its wholly-owned subsidiary, KHPG Biotech, has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the clinical trial application of injectable KH815. Injectable KH815 is a novel dual-load antibody-drug conjugate independently developed by KHPG Biotech, which has potential anti-resistance properties targeting trophoblast cell surface antigen 2, indicated for advanced solid tumors